Aktienanalyse zu Kalvista Pharmaceuticals Inc (KALV)KALVKalvista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

KalVista Pharmaceuticals is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 to deploy. The stock is already trading right around the deal price of $27 in pre-market, which limits upside from here. Because the company has been acquired for $27 per share in cash, the trade is now mainly a merger-arbitrage setup rather than a normal long-term investment. Since the user is impatient and does not want to wait for a better entry, the direct answer is to hold rather than buy aggressively at this level.

1 analysts cover KALV: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 34.38.